ABCDx (Advanced Brain Companion Diagnostics) is a privately-funded start-up company founded in 2014 by three experienced individuals: Two eminent researchers from the Faculty of Medicine of the University of Geneva and the Vall d’Hebron Research Institute (VHIR) at Vall d’Hebron Hospital, Barcelona. Recognized as key opinion leaders in the field of brain biomarkers, they combine expertise in biomarker discovery, validation and clinical experience. The third founder of ABCDx is an experienced industry and licensing executive with experience in both established and start-up diagnostic and pharmaceutical ventures.
ABCDx is dedicated to the development, validation, education and use of biomarker and biomarker panel tests for the assessment and indication of appropriate and timely clinical decisions in patients with a variety of brain injury conditions ranging from traumatic injury to stroke and post-stroke infections.
ABCDx has completed the acquisition of exclusive commercial rights to patent applications that seek to protect the use of individual biomarkers and panels of biomarkers to categorize, differentiate and indicate treatment and management for patients with brain injury in the following categories:
- Detection of mild Traumatic Brain Injury
- Differentiation between ischemic and hemorrhagic stroke
- Earlier identification of risk of post-stroke infection and other complications
ABCDx SA believes that use of its biomarker panels and its expertise will have the capability of transforming care of many brain injury patients by indicating appropriate and timely life-saving or life-changing treatments which could greatly improve clinical outcomes for a significantly larger proportion of afflicted patients.